Chemical Research in Chinese Universities ›› 2022, Vol. 38 ›› Issue (4): 928-934.doi: 10.1007/s40242-022-2116-8

• Articles • Previous Articles     Next Articles

A DNA Nano-train Carrying a Predefined Drug Combination for Cancer Therapy

HUANG Qin1,2, LIU Xin1, ZHANG Pengge2, WU Zhan1, ZHAO Zilong2   

  1. 1. Key Laboratory of Chemical Biology &Traditional Chinese Medicine Research of Ministry of Education, College of Chemistry and Chemical Engineering, Hunan Normal University, Changsha 410081, P. R. China;
    2. Molecular Science and Biomedicine Laboratory(MBL), State Key Laboratory of Chemo/Biosensing and Chemometrics, College of Chemistry and Chemical Engineering, Hunan University, Changsha 410012, P. R. China
  • Received:2022-03-29 Revised:2022-05-04 Online:2022-08-01 Published:2022-07-01
  • Contact: ZHAO Zilong;WU Zhan E-mail:zlzhao@hnu.edu.cn;zhanwu@hunnu.edu.cn
  • Supported by:
    This work was supported by the National Natural Science Foundation of China(Nos.21974040, 22177028, 91953105).

Abstract: Herein, we reported a tumor cell-targeting aptamer-nano-train to deliver paclitaxel(PTX) and combretastatin A4(CA4) at a predefined ratio to cancer cells based on DNA nanotechnology. Such a drug-carrying aptamer-nano-train(aptamer-NT-PTX/CA4) was prepared via self-assembly of two DNA hairpins, which were conjugated with PTX and CA4, respectively, induced by aptamer trigger. Our research revealed that the aptamer-NT-PTX/CA4 could specifically recognize CD71-positive cancer cells, but not CD71-negative healthy normal cells, and achieve synergistic therapeutic effect on cancer cells. The aptamer-nano-train-based strategy is simple and efficient, and provides a new platform for drug combination cancer therapy.

Key words: Targeted therapy, Drug combination cancer therapy, Aptamer, DNA nanostructure